AVEO Pharmaceuticals Inc. (AVEO) Sees Significant Decrease in Short Interest
AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 987,840 shares, a drop of 21.8% from the August 31st total of 1,262,761 shares. Currently, 1.7% of the shares of the company are short sold. Based on an average daily volume of 160,433 shares, the short-interest ratio is currently 6.2 days.
Several equities research analysts recently issued reports on AVEO shares. Piper Jaffray Cos. reiterated a “buy” rating on shares of AVEO Pharmaceuticals in a research note on Thursday, June 16th. FBR & Co reiterated a “buy” rating on shares of AVEO Pharmaceuticals in a research note on Monday, June 20th.
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) opened at 0.89 on Friday. The firm’s market capitalization is $67.51 million. The firm’s 50-day moving average is $0.92 and its 200 day moving average is $0.95. AVEO Pharmaceuticals has a 12 month low of $0.81 and a 12 month high of $1.47.
Several institutional investors have recently bought and sold shares of the company. Spark Investment Management LLC purchased a new position in shares of AVEO Pharmaceuticals during the second quarter valued at $281,000. Bridgeway Capital Management Inc. increased its position in AVEO Pharmaceuticals by 63.7% in the second quarter. Bridgeway Capital Management Inc. now owns 514,051 shares of the biopharmaceutical company’s stock valued at $494,000 after buying an additional 200,000 shares during the period. Renaissance Technologies LLC increased its position in AVEO Pharmaceuticals by 6.0% in the first quarter. Renaissance Technologies LLC now owns 2,094,900 shares of the biopharmaceutical company’s stock valued at $1,927,000 after buying an additional 119,000 shares during the period. Vanguard Group Inc. increased its position in AVEO Pharmaceuticals by 1.1% in the second quarter. Vanguard Group Inc. now owns 2,470,485 shares of the biopharmaceutical company’s stock valued at $2,374,000 after buying an additional 27,304 shares during the period. Finally, New Leaf Venture Partners L.L.C. bought a new position in AVEO Pharmaceuticals during the second quarter valued at approximately $2,490,000. 39.10% of the stock is currently owned by institutional investors.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Stock Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.